Results 181 to 190 of about 48,143 (212)
Some of the next articles are maybe not open access.
Phosphodiesterase Inhibitors and Cerebral Vasospasm
Archives of Neurology, 1975Experimental cerebral vasospasm was studied in cat and monkey models. In the cat, the basilar artery was exposed by a transclival approach and spasm induced by the application of blood to the vessel. In the monkey, spasm was produced by injecting blood into the subarachnoid space.
Eugene S. Flamm +3 more
openaire +4 more sources
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A. Cockrill, Aaron B. Waxman
openaire +3 more sources
Xanthines and Phosphodiesterase Inhibitors
2016Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
Clive P. Page, Domenico Spina
openaire +2 more sources
Inhibitors of phosphodiesterases in the treatment of cough
Respiratory Physiology & Neurobiology, 2018A group of 11 enzyme families of metalophosphohydrolases called phosphodiesterases (PDEs) is responsible for a hydrolysis of intracellular cAMP and cGMP. Xanthine derivatives (methylxanthines) inhibit PDEs without selective action on their single isoforms and lead to many pharmacological effects, e.g.
Daniela Mokra +3 more
openaire +3 more sources
Phosphodiesterase inhibitors in psychiatric disorders
Psychopharmacology, 2023Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi +5 more
openaire +2 more sources
Disaggregatory action of phosphodiesterase inhibitors
Pharmacological Research Communications, 1981Summary Papaverine and three hypotensive xanthines were shown to disaggregate platelet clumps in anaesthetized cats. The order of disaggregatory potency was: IMBX > papaverine > > aminophylline ≫ xantinol nicotinate. This effect was not associated with the release of prostacyclin. It is concluded that disaggregatory action of papaverine and xanthines
Ryszard J. Gryglewski +2 more
openaire +3 more sources
The new inotropic phosphodiesterase inhibitors
Archives Internationales de Physiologie et de Biochimie, 1984Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D El Allaf +2 more
openaire +3 more sources
Phosphodiesterase inhibitors in clinical urology
Expert Review of Clinical Pharmacology, 2013To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the ...
Markus A. Kuczyk +2 more
openaire +3 more sources
Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design, 2005An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Ashok Tehim +3 more
openaire +3 more sources
The role of phosphodiesterase inhibitors in impotence
Expert Opinion on Investigational Drugs, 1997Penile erection is mediated by nitric oxide (NO) and its second messenger cyclic guanosine monophosphate (cGMP). The activity of cGMP is modulated by the enzyme phosphodiesterase (PDE). The most important physiological isoform of the enzyme in the penis is PDE5.
openaire +3 more sources